Serum adipocytokine levels in prostate cancer patients

Urologia Internationalis

Volumn 82, Issue 2, 2009, Pages 203-208

  Arisan, Elif Damla ^b,c   Arisan, Serdar ^a   Atis, Gokhan ^a   Palavan Unsal, Narcin ^a   Ergenekon, Erbil ^a  

^a SISLI ETFAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b Faculty of Science and Letters   (Turkey)

^c ISTANBUL KULTUR UNIVERSITY   (Turkey)

Author keywords

Adiponectin; Insulin; Leptin; Obesity; Prostate cancer

Indexed keywords

ADIPONECTIN; LEPTIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL;

ADIPONECTIN; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; BODY MASS INDEX; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INSULIN; LEPTIN; LIPIDS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 63449127688     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000200801     Document Type: Article

References (28)

1. Koerner A, Kratzsch J, Kiess W: Adipocytokines: leptin - the classical, resistin - the controversical, adiponectin - the promising, and more to come. Best Pract Res Clin Endocrinol etab 2005; 19: 525-546.
2. Freedland J: Obesity and prostate cancer: a growing problem. Clin Cancer Res 2005; 11: 6763-6766.
3. Fair WR, Fleshner NE, Heston W: Cancer of the prostate: a nutritional disease? Urology 1997; 50: 840-848.
4. Freedland SJ, Giovannucci E, Platz EA: Are findings from studies of obesity and prostate cancer really in conflict? Cancer Causes Control 2006; 17: 5-9.
5. Hu E, Liang P, Spiegelman BM: AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996; 271: 10697-10703.
6. Chen DC, Chung YF, Yeh YT, Chaung HC, Kuo FC, Fu OY, Chen HY, Hou MF, Yuan SS: Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett 2005; 237: 109-114.
7. Michalakis K, Williams CJ, Mitsiades N, Blakeman J, Balafouta-Tselenis S, Giannopoulos A, Mantzoros CS: Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. Cancer Epidemiol Biomarkers Prev 2007; 2: 308-313.
8. Baillargeon J, Rose DP: Obesity, adipokines, and prostate cancer. Int J Oncol 2006; 28: 737-745.
9. Mistry T, Digby JE, Chen J, Desai KM, Randeva HS: The regulation of adiponectin receptors in human prostate cancer cell lines. Biochem Biophys Res Commun 2006; 348: 832-838.
10. Goktas S, Yilmaz MI, Caglar K, Sonmez A, Kilic S, Bedir S: Prostate cancer and adiponectin. Urology 2005; 65: 1168-1172.
11. Somasundar P, et al: Prostate cancer cell proliferation are influenced by leptin. J Surg Res 2004; 118: 71-82.
12. Considine RV, Sinha MK, Heiman ML, et al: Serum immunoreactive leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 292-295.
13. Saglam K, Aydur E, Yilmaz MI, et al: Leptin influences cellular differentiation and progression in prostate cancer. J Urol 2003; 169: 1308-1311.
14. Mistry T, Digby JE, Desai KM, Randeva HS: Obesity and prostate cancer: a role for adipokines. Eur Urol 2007; 52: 46-53.
15. Stattin P, Soderberg S, Hallmans G, Bylund A, Kaaks R, Stenman UH, Bergh A, Olsson T: Leptin is associated with increased prostate cancer risk: a nested case-referent study. J Clin Endocrinol Metab 2001; 86: 1341-1345.
16. Gade-Andavolu R, Cone LA, Shu S, Morrow A, Kowshik B, Andavolu MV: Molecular interactions of leptin and prostate cancer. Cancer J 2006; 12: 201-206.
17. Bosland MC, Oakley-Girvan I, Whittemore AS: Dietary fat, calories, and prostate cancer risk. J Natl Cancer Inst 1999; 91: 489-491.
18. Andersson SO, Wolk A, Bergstrom R, et al: Body size and prostate cancer: a 20-year follow- up study among 135,006 Swedish construction workers. J Natl Cancer Inst 1997; 89: 385-389.
19. Calle EE, Rodriguez C, Walker-Thurmond K, et al: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348:1625-1638.
20. Hsing AW, Gao YT, Chua S, et al: Insulin resistance and prostate cancer risk. J Natl Cancer Inst 2003; 95: 67-71.
21. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC: Height, body weight, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 1997; 6: 557-563.
22. Freedland SJ, Sokoll LJ, Platz EA, Mangold LA, Bruzek DJ, Mohr P, Yiu SK, Partin AW: Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy. J Urol 2005; 174: 1266-1270.
23. Mantzoros CS, Bolhke K, Moschos S, Cramer DW: Leptin in relation to carcinoma in situ of the breast: a study of pre-menopausal cases and controls. Int J Cancer 1999; 80: 523-526.
24. Freedland SJ: Obesity and prostate cancer: a growing problem. Clin Cancer Res 2005; 11: 6763-6766.
25. Freedland SJ, Sokoll LJ, Mangold LA, Bruzek DJ, Mohr P, Yiu SK, Epstein JI, Partin AW: Serum leptin and pathological findings at the time of radical prostatectomy. J Urol 2005; 173: 773-776.
26. Nazian SJ, Cameron DF: Temporal relation between leptin and various indices of sexual maturation in the male rat. J Androl 1999; 20: 487-491.
27. Chang S, Hursting SD, Contois JH, et al: Leptin and prostate cancer. Prostate 2001; 46: 62-67.
28. Hsing AW, Chua S Jr, Gao YT, et al: Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst 2001; 93: 783-789.